Medications are developed by the pharmaceutical industry starting with the discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I to Phase III), and if the data are positive, may lead to Food and Drug Administration (FDA) approval. Once approved, post-marketing surveillance for safety is required as long as the drug is marketed to consumers. This phase may also include clinical trial Phase IV studies if additional safety testing is required. This process usually takes between ten to fifteen years, with clinical development taking seven to ten years of that time (1). Clinical development can be facilitated by a clinical development Project Management Office (PMO) at pharmaceutical companies. Clinical development PMOs provide value by establishing processes that can be universally adopted by the pharmaceutical industry. This can help simplify product development, and as a result, accelerate time to market. Clinical development project management is a relatively new field in the pharmaceutical industry, and there are few publications and literary reviews regarding standardized best practices, current best practices, and potential best practices for clinical development.
Decreasing the time it takes a drug to reach market can help patients live longer and/or improve their quality of life. Time to market is often driven by the time it takes to test the product in clinical settings. This thesis is focused on analyzing the clinical development project management practices in order to reduce the time to market. The goals of this project were to identify best practices in clinical development project management, compile a reference standard, develop a rubric, evaluate the rubric on a comparator company, and make a recommendation regarding actions required for the comparator company to achieve the reference standard.
","abstract_html":"<p>Medications are developed by the pharmaceutical industry starting with the discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I to Phase III), and if the data are positive, may lead to Food and Drug Administration (FDA) approval. Once approved, post-marketing surveillance for safety is required as long as the drug is marketed to consumers. This phase may also include clinical trial Phase IV studies if additional safety testing is required. This process usually takes between ten to fifteen years, with clinical development taking seven to ten years of that time <a>(1)</a>. Clinical development can be facilitated by a clinical development Project Management Office (PMO) at pharmaceutical companies. Clinical development PMOs provide value by establishing processes that can be universally adopted by the pharmaceutical industry. This can help simplify product development, and as a result, accelerate time to market. Clinical development project management is a relatively new field in the pharmaceutical industry, and there are few publications and literary reviews regarding standardized best practices, current best practices, and potential best practices for clinical development.</p> <p>Decreasing the time it takes a drug to reach market can help patients live longer and/or improve their quality of life. Time to market is often driven by the time it takes to test the product in clinical settings. This thesis is focused on analyzing the clinical development project management practices in order to reduce the time to market. The goals of this project were to identify best practices in clinical development project management, compile a reference standard, develop a rubric, evaluate the rubric on a comparator company, and make a recommendation regarding actions required for the comparator company to achieve the reference standard.</p>","abstract_has_math":false,"creators":["Guinto, Russell"],"institution":null,"degree_name":"Master of Science","degree_level":"Master's Thesis","degree_discipline":"Biological Sciences","degree_department":null,"school":null,"contributors":["Kathryn Davidson, MA, MS","Maggie Louie, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-08-01T07:00:00Z","date_published":"2018-08-01T07:00:00Z","updated_at":"2026-07-24T02:04:51Z","subjects":["Project Management","Clinical Development","Best Practices","Standards","Methodologies","Techniques","Biotechnology","Business Administration, Management, and Operations"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://scholar.dominican.edu/masters-theses/354","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Kathryn Davidson, MA, MS","Maggie Louie, PhD"]},{"key":"dc:creator","label":"Author","values":["Guinto, Russell"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2018-08-24T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master's Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Project Management","Clinical Development","Best Practices","Standards","Methodologies","Techniques","Biotechnology","Business Administration, Management, and Operations"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholar.dominican.edu/masters-theses/354"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Medications are developed by the pharmaceutical industry starting with the discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I to Phase III), and if the data are positive, may lead to Food and Drug Administration (FDA) approval. Once approved, post-marketing surveillance for safety is required as long as the drug is marketed to consumers. This phase may also include clinical trial Phase IV studies if additional safety testing is required. This process usually takes between ten to fifteen years, with clinical development taking seven to ten years of that time (1). Clinical development can be facilitated by a clinical development Project Management Office (PMO) at pharmaceutical companies. Clinical development PMOs provide value by establishing processes that can be universally adopted by the pharmaceutical industry. This can help simplify product development, and as a result, accelerate time to market. Clinical development project management is a relatively new field in the pharmaceutical industry, and there are few publications and literary reviews regarding standardized best practices, current best practices, and potential best practices for clinical development.
Decreasing the time it takes a drug to reach market can help patients live longer and/or improve their quality of life. Time to market is often driven by the time it takes to test the product in clinical settings. This thesis is focused on analyzing the clinical development project management practices in order to reduce the time to market. The goals of this project were to identify best practices in clinical development project management, compile a reference standard, develop a rubric, evaluate the rubric on a comparator company, and make a recommendation regarding actions required for the comparator company to achieve the reference standard.
"]},{"key":"dc:title","label":"Title","values":["Best Practices in a Clinical Development Project Management Office (PMO) to Achieve a Reference Standard in the Pharmaceutical Industry"]}]}],"canonical_facts":{"dc:contributor":["Kathryn Davidson, MA, MS","Maggie Louie, PhD"],"dc:creator":["Guinto, Russell"],"dc:date.available":["2018-08-24T07:00:00Z"],"dc:description.abstract":["Medications are developed by the pharmaceutical industry starting with the discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I to Phase III), and if the data are positive, may lead to Food and Drug Administration (FDA) approval. Once approved, post-marketing surveillance for safety is required as long as the drug is marketed to consumers. This phase may also include clinical trial Phase IV studies if additional safety testing is required. This process usually takes between ten to fifteen years, with clinical development taking seven to ten years of that time (1). Clinical development can be facilitated by a clinical development Project Management Office (PMO) at pharmaceutical companies. Clinical development PMOs provide value by establishing processes that can be universally adopted by the pharmaceutical industry. This can help simplify product development, and as a result, accelerate time to market. Clinical development project management is a relatively new field in the pharmaceutical industry, and there are few publications and literary reviews regarding standardized best practices, current best practices, and potential best practices for clinical development.
Decreasing the time it takes a drug to reach market can help patients live longer and/or improve their quality of life. Time to market is often driven by the time it takes to test the product in clinical settings. This thesis is focused on analyzing the clinical development project management practices in order to reduce the time to market. The goals of this project were to identify best practices in clinical development project management, compile a reference standard, develop a rubric, evaluate the rubric on a comparator company, and make a recommendation regarding actions required for the comparator company to achieve the reference standard.
"],"dc:identifier":["https://scholar.dominican.edu/masters-theses/354"],"dc:subject":["Project Management","Clinical Development","Best Practices","Standards","Methodologies","Techniques","Biotechnology","Business Administration, Management, and Operations"],"dc:title":["Best Practices in a Clinical Development Project Management Office (PMO) to Achieve a Reference Standard in the Pharmaceutical Industry"],"thesis:degree_discipline":["Biological Sciences"],"thesis:degree_level":["Master's Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-07-24T02:04:51Z"}